We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Pfizer Inc | NYSE:PFE | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.16 | 0.58% | 27.86 | 27.905 | 27.52 | 27.86 | 60,567,753 | 00:59:06 |
From May 2019 to May 2024
By Josh Beckerman
Biopharmaceutical company SpringWorks Therapeutics Inc. (SWTX) said its initial public offering of 9 million shares priced at $18 each.
On Sept. 3, SpringWorks said it expected to offer 7.35 million shares at $16 to $18 each. The expected size was increased to 9 million shares earlier Thursday.
Pfizer Inc. (PFE), which licensed nirogacestat to SpringWorks in 2017, will have a post-IPO stake of about 10.9%, according to a filing. Bain Capital and OrbiMed Advisors will each own about 17%.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
September 12, 2019 18:52 ET (22:52 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Pfizer Chart |
1 Month Pfizer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
